

RECEIVED G-AU 1632

TECH CENTER 1600/2900

Patent Docket P1219P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of:</p> <p>Stewart et al.</p> <p>Serial No.: 09/522,342</p> <p>Filed: March 9, 2000</p> <p>For: <i>Fibroblast Growth Factor-19 (FGF-19) Nucleic Acids and Polypeptides and Methods of Use for the Treatment of Obesity</i></p>	<p>Group Art Unit: Unknown</p> <p>Examiner: Unknown</p> <hr/> <p><b>CERTIFICATE OF MAILING</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>October 24, 2000</p> <p><i>Teri Renshaw</i></p> <p>Teri Renshaw</p>
---	---

**PETITION TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.48(a) AND  
ADDITION OF PRIORITY CLAIMS**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This is a petition under 37 C.F.R. § 1.48(a) to correct inventorship in the above captioned case. In support of this petition, Applicants enclose the following:

- (1) statements from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his or her part;
- (2) newly executed declaration and power of attorney documents by the actual inventors;
- (3) the petition fee set forth in 37 C.F.R. § 1.17(i) (the Commissioner is authorized to charge the petition fee set forth in 37 C.F.R. § 1.17(i) as well as any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 07-0630); and
- (4) written consent of the assignee.

**Serial No.:** 09/284,663

**Filed:** April 15, 1999

The error in inventorship in this application arose without any deceptive intention on the part of the persons originally named as inventors herein or on the part of the persons who through error were not named as inventors herein.


Additionally, Applicants note that the newly executed substitute declarations enclosed herewith reference priority claims under 35 U.S.C. § 120 to three previously filed U.S. and/or PCT patent applications to which priority was not previously claimed. Applicants respectfully submit that the above captioned patent application is entitled to validly claim priority to these three previously filed applications.

The Commissioner is authorized to charge any fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 07-0630.

The examiner is invited to contact the undersigned at (650) 225-4461 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

By:   
Mark T. Kresnak, Ph.D.  
Reg. No. 42,767

1 DNA Way, MS 49  
South San Francisco, CA 94080  
Phone: (650) 225-4461  
Fax: (650) 952-9881